Assess vasculitis quality of life with OUI’s clinical tools
Vasculitis is a complex and unpredictable disease, primarily caused by inflammation of the blood vessels.
Vasculitis is a complex and unpredictable disease, primarily caused by inflammation of the blood vessels.
A powerful new tool - launched by the Ellison Institute of Technology (EIT) – is demonstrative of the impact of university research on global health.
The Mixergy cylinder concept was originally developed in 2014 by Pete Armstrong and Ren Kang during their time at Oxford University.
Oxford University Innovation announces appointment of their new Chief Operating Officer.
Since 1980, Oxford University Innovation (OUI) has overseen the licensing and commercialisation of the Dawes-Redman Cardiotocography (CTG) analysis system. This technology, used worldwide to monitor fetal health during pregnancy, is considered one of the University of Oxford’s most successful clinical advances.
Oxford University Innovation celebrates the launch of OXCCU's demonstration plant
The team behind MariTest, a non-invasive test for malaria, are the winners of this year’s Student Entrepreneurship Programme
Four internet-based therapies developed by experts at the University of Oxford’s Department of Experimental Psychology and Department of Psychiatry are proving helpful for patients with social anxiety disorder and post-traumatic stress disorders and for children with anxiety disorders.
A new company, MatchBio, founded by Professors Omer Dushek and Anton van der Merwe from the Dunn School of Pathology, is set to revolutionise immunotherapy by enhancing CAR T therapy.
Apollo Therapeutics will inject capital and expertise into pipeline of potentially lifesaving medicines through an agreement with the University of Oxford. The collaboration highlights a shared strategic intent to develop new therapeutics based on breakthroughs in biology and basic medical research at the University of Oxford.